Linker Information
General Information of This Linker
| Linker ID |
LIN0DSBFC
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
6-Maleimidocaproic acid
|
|||||
| Linker Type |
Flexible reactive (thiol) linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
| Structure |
|
|||||
| Formula |
C10H13NO4
|
|||||
| Isosmiles |
[H]OC(=O)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C(=O)C([H])=C([H])C1=O
|
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C10H13NO4/c12-8-5-6-9(13)11(8)7-3-1-2-4-10(14)15/h5-6H,1-4,7H2,(H,14,15)
|
|||||
| InChIKey |
WOJKKJKETHYEAC-UHFFFAOYSA-N
|
|||||
| IUPAC Name |
6-(2,5-dioxopyrrol-1-yl)hexanoic acid
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
211.217
|
Polar area
|
74.68
|
||
|
Complexity
|
211.0844579
|
xlogp Value
|
0.5564
|
|||
|
Heavy Count
|
15
|
Rot Bonds
|
6
|
|||
|
Hbond acc
|
4
|
Hbond Donor
|
1
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BAT8001 [Phase 3 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
41.40%
|
|||
| Patients Enrolled |
HER2-positive locally advanced or metastatic breast cancer.
|
||||
| Administration Dosage |
Patients received BAT8001 intravenously in a 21-day cycle, with dose escalation in 5 cohorts: 1.20, 2.40, 3.60, 4.80, and 6.00 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04189211 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
|
||||
| Primary Endpoint |
For BAT8001, 3.60 mg/kg was determined to be the MTD.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04185649 | Clinical Status | Phase 3 | ||
| Clinical Description |
A clinical study evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer - a multicenter, randomized, open-label, positive-controlled, superiority phase 3 clinical trial in china.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04151329 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
Evaluation for the safety of BAT1306 and BAT8001 injection for the treatment of patients with HER2-positive advanced solid tumors phase 1/2a clinical trials of sexual, tolerability and pharmacokinetic characteristics.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04189211 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
|
||||
BAT8003 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [5] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03884517 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open, escalating phase 1 clinical trial of BAT8003 (for injection) on the safety, tolerability and pharmacokinetics for patients with advanced epithelial cancer.
|
||||
References